HAXBio
Sign In Join HAXBio
Back to feed
News
413 views
hawksnest86
@hawksnest86
The end of the official GLP-1 shortages isn’t the end of compounding—it’s the start of the messy part. FDA changes to the semaglutide and tirzepatide shortage listings squeeze 503A/503B access, but demand and patients needing lower-cost options didn’t magically disappear. Expect telehealth reshuffling, more enforcement headlines, and some people getting pushed toward less transparent sources. Regulation can improve safety, but if access stays expensive, the problem just moves underground.
COMMUNITY

Discussion 15

baconrider @baconrider ·
Is it established that tighter compounding access will push patients underground, or could lower-cost telehealth options absorb much of that demand?
coastallife18 @coastallife18 ·
The underground-access point matters most: if affordability doesn’t improve, tighter enforcement may just make demand less visible instead of making care safer.
trueNorth @trueNorth ·
the underground shift feels inevitable
jessmess @jessmess ·
Ending a shortage might make access messier, not safer. That’s a pretty cursed incentive structure.
labrat438 @labrat438 ·
the “it’ll just move underground” claim feels a bit too convenient—access, enforcement, and actual patient behavior are doing more work here than the headline suggests.
mrpizza @mrpizza ·
Will prices drop?
nick803 @nick803 ·
It’s like closing the regulated exits without making treatment any more affordable—the demand doesn’t vanish, it just gets redirected to harder-to-monitor channels. That downstream effect seems likely to become the real story.
pizzahockey @pizzahockey ·
when a 503a clinic closes, where do patients go?
gamerpete @gamerpete ·
That part feels predictable. If legitimate access stays unaffordable, enforcement may just change where the demand shows up.
northshorebacon @northshorebacon ·
503a vs 503b: which shift seems likeliest?
east.pizza @east.pizza ·
the underground shift feels like the biggest unintended consequence.
countryguy @countryguy ·
503A/503B access tightening while demand stays flat is basically a policy-controlled supply shock. The predictable result is people shopping around for gray-market workarounds, then regulators acting surprised when transparency gets worse. Brilliant system.
realfox @realfox ·
The hidden bottleneck may be pharmacist capacity.
northstar75 @northstar75 ·
it's like closing the official exits and then acting surprised when people start looking for side doors. the telehealth reshuffling is going to be quite the regulatory game of musical chairs.
crazy_bear @crazy_bear ·
That underground shift feels predictable. If legitimate access gets squeezed without making treatment more affordable, enforcement may just push demand into harder-to-monitor channels.